BMJ  2007;335:322 (18 August), doi:10.1136/bmj.39304.603762.DB

News

FDA needs more funding, NEJM says, amid questions about antidiabetes drug

New York

The first 150 words of the full text of this article appear below.

The US Food and Drug Administration needs more funding to do its job, say two articles in the New England Journal of Medicine (NEJM) related to reports of an increased cardiovascular risk associated with rosiglitazone (marketed as Avandia), used to treat type 2 diabetes.

Earlier this year the FDA placed its most serious "black box" warnings on rosiglitazone, which is made by GlaxoSmithKline, and pioglitazone (Actos), made by Takeda, saying that they increased the risk of congestive heart failure (BMJ 2007;334:1237 doi: 10.1136/bmj.39244.394456.DB).

Clifford Rosen, who chaired the FDA advisory committee that looked into the drug, has written a commentary in the NEJM (doi: 10.1056/NEJMp078167). "The basic plot of the rosiglitazone story quickly became obvious to the . . . committee: a new ‘wonder drug,' approved prematurely and for the wrong reasons by a weakened and underfunded government agency subjected to pressure from industry, had . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

FDA committees say keep rosiglitazone available but increase warnings

Janice Hopkins Tanne
BMJ 2007 335: 223. [Extract] [Full Text] [PDF]

FDA places "black box" warning on antidiabetes drugs

Janice Hopkins Tanne
BMJ 2007 334: 1237. [Extract] [Full Text] [PDF]

Study indicates diabetes drug linked to cardiovascular death

Janice Hopkins Tanne
BMJ 2007 334: 1073. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Peacock, Z. S., Pogrel, M. A., Schmidt, B. L. (2008). Exploring the Reasons for Delay in Treatment of Oral Cancer. Journal of the American Dental Association 139: 1346-1352 [Abstract] [Full text]  

Online poll

Find out more >>